Scientific exchange · Dr. Javier Kimura

01 Jun 2026 · In person · Dr. Javier Kimura, Gustave Roussy · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0137—

Capture insight from this engagement

Location: Gustave Roussy
Therapeutic area: Nephrology
Country: France
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

APRIL pathway mechanism
eGFR slope interpretation
Treatment burden and fatigue

Scientific content used

Surrogate-endpoint evidence review
NPH mechanism-of-action deck

Questions raised

How does proteinuria reduction at 9 months translate to eGFR benefit?

Notes

Scientific exchange with renal pathologist at Gustave Roussy. Discussed april pathway mechanism, egfr slope interpretation, treatment burden and fatigue.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 4
Depth of exchange: 3
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0137

Audit history (0)

All create, update and approval events for this record

No audit events in sample data